Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 6/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | STAT3 | P40763 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18123831 | 0.91 | KDM4E (0.38) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL18123592 | 0.91 | KDM4E (0.38) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL12493926 | 0.85 | MAPT (0.48) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL18123828 | 0.83 | LMNA (0.39) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL18123765 | 0.82 | NCEH1 (0.37) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL12494851 | 0.80 | LMNA (0.39) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL17145346 | 0.80 | KLKB1 (0.46) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL20816208 | 0.80 | PDE4A (0.36) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL18123703 | 0.80 | NCEH1 (0.40) | PDE4APDE4BPDE4CPDE4DRECQL | |
| SCHEMBL12525445 | 0.79 | PDE4A (0.38) | PDE4APDE4BPDE4CPDE4DLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392098-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | BOSTON BIOMEDICAL, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-10800752-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | BOSTON BIOMEDICAL, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190084955-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | BOSTON BIOMEDICAL, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-10183925-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | BOSTON BIOMEDICAL, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180111914-A1 | WATER-SOLUBLE PRODRUGS | BOSTON BIOMEDICAL, INC. (US) | 2018-04-26 | — | — | US | disclosed |
| WO-2016157052-A1 | WATER-SOLUBLE PRODRUGS | BOSTON BIOMEDICAL, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392098-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | NR0B1, NR0B2, NR2C2 | PDE4A 2306/4885PDE4B 1848/4885PDE4C 2090/4885 |
| US-20180111914-A1 | WATER-SOLUBLE PRODRUGS | NR0B2, NR0B1, AVPR1B | PDE4A 1879/4885PDE4B 1563/4885PDE4C 1886/4885 |
| US-20190084955-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | NR0B1, NR0B2, NR2C2 | PDE4A 2306/4885PDE4B 1848/4885PDE4C 2090/4885 |
| US-10800752-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | NR0B1, NR0B2, NR2C2 | PDE4A 2306/4885PDE4B 1848/4885PDE4C 2090/4885 |
| US-10183925-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | NR0B1, NR0B2, NR2C2 | PDE4A 2306/4885PDE4B 1848/4885PDE4C 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.